Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases

Details for Australian Patent Application No. 2008273892 (hide)

Owner AstraZeneca AB

Inventors Pike, Kurt Gordon; Finlay, Maurice Raymond Verschoyle

Agent Davies Collison Cave

Pub. Number AU-A-2008273892

PCT Pub. Number WO2009/007751

Priority 60/948,570 09.07.07 US

Filing date 8 July 2008

Wipo publication date 15 January 2009

International Classifications

C07D 413/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

A61K 31/5377 (2006.01)

A61P 35/00 (2006.01) Antineoplastic agents

C07D 417/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

Event Publications

28 January 2010 PCT application entered the National Phase

  PCT publication WO2009/007751 Priority application(s): WO2009/007751

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008273898-Tiltable column

2008273891-Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/ or PI3K